A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma
A phase 1/2 trial of AZD5851 in hepatocellular carcinoma, run by AstraZeneca, active and no longer recruiting.
Overview
A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma is a phase 1/2 interventional study registered as NCT06084884 by AstraZeneca, with 94 participants enrolled, started 2023-12-14 and due to reach its primary completion in 2027-12-13. Interventions recorded: AZD5851.
Similar pages
not linked directly; found by shared links- TrialA Study of PTX-9908 Injection for Non-resectable HCC with TACE
Shares Hepatocellular carcinoma and the tag pipeline.
- TrialABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma
Shares Hepatocellular carcinoma and the tag pipeline.
- TrialGPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC
Shares Hepatocellular carcinoma and the tag pipeline.
- TrialEfficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma
Shares Hepatocellular carcinoma and the tag pipeline.
- TrialOri-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
Shares Hepatocellular carcinoma and the tag pipeline.
- TrialTo Evaluate Safety and Efficacy of FB-1603 in Hepatocellular Carcinoma Patient Receiving Transarterial Chemoembolization
Shares Hepatocellular carcinoma and the tag pipeline.
- TrialA Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.
Shares Hepatocellular carcinoma and the tag pipeline.
- TrialNWRD06 DNA Plasmid for HCC After Curative Resection.
Shares Hepatocellular carcinoma and the tag pipeline.